Scarica l'app Stockscreener
47.80
0.04%
-0.03
Precedente Chiudi:
$47.83
Aprire:
$47.8
Volume 24 ore:
88,810
Relative Volume:
0.12
Capitalizzazione di mercato:
$1.23B
Reddito:
-
Utile/perdita netta:
$11.77M
Rapporto P/E:
82.63
EPS:
0.5785
Flusso di cassa netto:
$-19.23M
1 W Prestazione:
+0.13%
1M Prestazione:
+104.32%
6M Prestazione:
+235.74%
1 anno Prestazione:
+82.27%
Intervallo 1D:
$47.80
$47.87
Intervallo di 1 settimana:
$47.67
$48.27
Portata 52W:
$11.56
$48.27
Tourmaline Bio Inc Stock (TRML) Company Profile
Nome
Tourmaline Bio Inc
Settore
Industria
Telefono
646-481-9832
Indirizzo
27 WEST 24TH STREET, NEW YORK
Confronta TRML con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
47.81 | 1.23B | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.98 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.75 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.66 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.21 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2023-12-15 | Iniziato | Jefferies | Buy |
| 2023-12-04 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2023-10-31 | Iniziato | Guggenheim | Buy |
| 2023-10-25 | Iniziato | Piper Sandler | Overweight |
| 2022-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mostra tutto
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
Identifying reversal signals in Tourmaline Bio Inc.Earnings Risk Summary & Safe Entry Zone Tips - newser.com
Using flow based indicators on Tourmaline Bio Inc.Portfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Technical analysis overview for Tourmaline Bio Inc. stockLong Setup & Consistent Growth Stock Picks - newser.com
Novartis commences tender offer to buy Tourmaline Bio - Medical Dialogues
Is Tourmaline Bio Inc. forming a bottoming baseTrade Risk Assessment & AI Based Buy/Sell Signal Reports - newser.com
Will Tourmaline Bio Inc. stock outperform growth indexesGDP Growth & Stock Portfolio Risk Control - newser.com
Tourmaline Bio stock hits 52-week high at 47.8 USD By Investing.com - Investing.com Nigeria
What MACD signals say about Tourmaline Bio Inc.2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
Tourmaline Bio stock hits 52-week high at 47.8 USD - Investing.com India
Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week HighHere's Why - MarketBeat
Tourmaline Bio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Can Tourmaline Bio Inc. recover in the next quarterWeekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Novartis announces commencement of tender offer to acquire Tourmaline Bio29.09.25News - Ariva
Novartis launches tender offer for Tourmaline Bio - MarketScreener
Custom strategy builders for tracking Tourmaline Bio Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - newser.com
Is Tourmaline Bio Inc a good long term investmentBull Market Opportunities & Outstanding Investment Returns - earlytimes.in
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 - GlobeNewswire Inc.
Tourmaline Bio (NASDAQ:TRML) Sets New 1-Year HighStill a Buy? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Upcoming Events - FinancialContent
Goldman Sachs Group Inc. Lowers Position in Tourmaline Bio, Inc. $TRML - MarketBeat
Wesbanco Bank Inc. Takes Position in Tourmaline Bio, Inc. $TRML - MarketBeat
Tourmaline Bio, Inc. Hits New 52-Week High of $47.76 - Markets Mojo
BMO Capital Markets Downgrades Tourmaline Bio (NASDAQ:TRML) to Market Perform - MarketBeat
Market Wrap: Is Tourmaline Bio Inc.’s growth already priced inEarnings Performance Report & Fast Gain Swing Trade Alerts - خودرو بانک
About Us - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML) - Eastern Progress
Fed Meeting: What is the next catalyst for Tourmaline Bio IncInsider Buying & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Quarterly Earnings: Is Tourmaline Bio Inc. stock a good dividend stockGold Moves & Free Expert Verified Stock Movement Alerts - khodrobank.com
Tourmaline Bio (NASDAQ:TRML) Downgraded by Piper Sandler to Neutral - MarketBeat
RSI Check: Does Tourmaline Bio Inc stock have upside surprise potentialJuly 2025 Levels & Real-Time Volume Spike Alerts - خودرو بانک
Big Picture: Is Tourmaline Bio Inc. gaining market shareJuly 2025 Spike Watch & Risk Controlled Swing Trade Alerts - خودرو بانک
Market Pulse: What are AA Mission Acquisition Corps technical support levelsSell Signal & Daily Profit Maximizing Trade Tips - خودرو بانک
Tourmaline Bio (NASDAQ:TRML) Cut to Neutral at Chardan Capital - MarketBeat
Guggenheim Reaffirms "Neutral" Rating for Tourmaline Bio (NASDAQ:TRML) - MarketBeat
Setup Watch: Whats Tourmaline Bio Incs historical returnWeekly Trade Summary & Weekly Sector Rotation Insights - خودرو بانک
Institution Moves: Is Tourmaline Bio Inc a cyclical or defensive stockWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - خودرو بانک
Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition - Yahoo Finance
BMO Capital Downgrades Tourmaline Bio to Market Perform From Outperform, Raises Price Target to $48 From $35 - MarketScreener
This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday - Benzinga
BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news - Investing.com Canada
905,000 Shares in Tourmaline Bio, Inc. $TRML Acquired by Octagon Capital Advisors LP - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Downgraded to "Hold" Rating by Truist Financial - MarketBeat
Novartis to Buy US Biotech Tourmaline Bio for $1.4 Billion - MSN
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpShould You Buy? - MarketBeat
Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows - Yahoo
Tourmaline Bio (NASDAQ:TRML) Cut to Hold at Lifesci Capital - MarketBeat
Tourmaline Bio Inc Azioni (TRML) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):